Elan and Wyeth's Alzheimer's hope fails to impress
This article was originally published in Scrip
Executive Summary
Elanand Wyethhave presented further disappointing results from a closely watched and failed Phase II trial of bapineuzumab, an investigational Alzheimer's disease treatment. Observers had had high hopes for the drug as it is the most developmentally advanced monoclonal antibody directly targeting beta-amyloid, a class of drugs thought to have the potential to reverse patients' neurodegeneration.
You may also be interested in...
Amgen reveals more details of denosumab's fracture benefit
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Targacept/AstraZeneca Alzheimer's hope fails in Phase II
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.
Gilead must conduct another study of cystic fibrosis drug, FDA says
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.